Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET
Company Participants
Christine Cassiano – EVP, Chief Corporate Affairs & Brand Strategy Officer
David Chang – Co-Founder, President, CEO & Director
Zachary Roberts – EVP, Research & Development & CMO
Geoff Parker – EVP & CFO
Conference Call Participants
Michael Yee – Jefferies
Tyler Van Buren – TD Cowen
Biren Amin – Piper Sandler
Brian Chang – JPMorgan
Matthew Biegler – Oppenheimer
Samantha Semenkow – Citi
John Newman – Canaccord Genuity
William Pickering – Bernstein
Operator
Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter and 2025 Conference Call. [Operator Instructions] Please be aware that, today’s conference call is being recorded.
I would like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Cassiano, please go ahead.
Christine Cassiano
Thank you, operator, and thanks to all of you for joining this call. After the market closed, Allogene issued a press release that provided a business update and financial results for the first quarter of 2025. This press release and today’s webcast are available on our website.
Following our prepared remarks, we will host a Q&A session. We recognize that historically, questions have been multifaceted, but note that we will endeavor to keep this call to under an hour.
I’m joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.
During today’s call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecast and financial guidance, among other
#Allogene #Therapeutics #ALLO #Earnings #Call #Transcript